Atara Biotherapeutics Inc


+0.11 (+0.60%)

quotes and stock data delayed 15 minutes

52 wk hi

52 wk low





Burn Rate (Qtr)


Mkt Cap


Avg Volume


*cash/burn updated:

Q3 '20

Company Profile

Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Tab-cel (tabelecleucel)

EBV (Epstein-Barr Virus)


Q3 2021


The Company remains on track to complete the BLA filing in Q3 2021, based on several key points of agreement with FDA as previously announced.


MS (Progressive Multiple Sclerosis)

Phase 2

Q1 2021


Enrollment and regulatory update expected in Q1 2021

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon